NCT00133536View on ClinicalTrials.gov

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza A/H5N1 Vaccine

Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.

DRUG

Placebo

Normal saline administered intramuscularly.

Trial Locations (4)

21201

University of Maryland Baltimore, Baltimore

63104

Saint Louis University, St Louis

90502

UCLA Center For Vaccine Research, Torrance

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00133536 - A/H5N1 Vaccine in Healthy Children Aged 2-9 Years | Biotech Hunter | Biotech Hunter